SCHEMBL22015807

SCHEMBL22015807

CCOc1ccc(N2CCCN(CCCSCCN)CC2)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 1/20 0.52
HRH3 Q9Y5N1 2/20 0.51
KCNH2 Q12809 1/20 0.51
DRD2 P14416 6/20 0.49
HTR1A P08908 4/20 0.49
HTR2A P28223 4/20 0.49
DRD3 P35462 4/20 0.49
HRH1 P35367 3/20 0.49
TMEM97 Q5BJF2 2/20 0.49
SIGMAR1 Q99720 2/20 0.49
MAPT P10636 6/20 0.48
TP53 P04637 1/20 0.48
MAPK1 P28482 2/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
ALDH1A1 P00352 3/20 0.44
KDM4E B2RXH2 3/20 0.44
GAA P10253 2/20 0.43
HTR2C P28335 1/20 0.43
MEN1 O00255 1/20 0.43
APP P05067 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24209202 0.80 HSD17B10 (0.50) HSD17B10HRH3KCNH2DRD2HTR1A
SCHEMBL17124880 0.77 DRD2 (0.60) HSD17B10HRH3KCNH2DRD2HTR1A
SCHEMBL24209206 0.77 HSD17B10 (0.46) HSD17B10HRH3KCNH2DRD2HTR1A
SCHEMBL18773677 0.73 KMT2A (0.60) HSD17B10HRH3KCNH2MAPTTP53
SCHEMBL24209136 0.73 ALDH1A1 (0.43) TMEM97MAPTTP53SMN1; SMN2ALDH1A1
SCHEMBL4724848 0.72 MAPT (0.69) HSD17B10HRH3KCNH2MAPTTP53
SCHEMBL27363642 0.72 MAPT (0.65) HSD17B10DRD2MAPTTP53MAPK1
SCHEMBL4720351 0.71 MAPT (0.68) HSD17B10HRH3KCNH2MAPTTP53
SCHEMBL8363117 0.70 KMT2A (0.66) HSD17B10HRH3DRD2MAPTTP53
SCHEMBL11354876 0.69 HSD17B10 (1.00) HSD17B10KCNH2DRD2HTR1AHTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2020099886-A1 LOX INHIBITORS THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) 2020-05-22 WO disclosed